Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

CML Expert Opinions

 

Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes

 

  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford
 
Heisterkamp Keynote JGM 2016

 

  

 

 Keynote Rowley Prize 2016:

Evolution in our leukemia research: From identification of BCR/ABL fusion to carbohydrate-mediated protection by the bone marrow environment
Professor Nora Heisterkamp

Children's Center for Cancer and Blood Diseases, Children's Hospital in Los Angeles (USA)

  • Localization of human ABL on chromosome 9
  • ABL is located on the Ph chromosome
  • Cloning of part of human c-ABL
  • Sequencing of pTyr site of c-ABL
  • Breakpoint in the 5' region of c-ABL in CML DNA
  • Use of chimeric 22/9 fragment to clone part of chromosome 9
  • Ph breakpoints are clustered in a breakpoint cluster region 
  • BCR or 'PHL' is part of a gene
  • A chimeric BCR-ABL mRNA is made
  • Research 1987 and after
Kantarjian Keynote JGM 2016  

Keynote Goldman Prize 2016:

Chronic Myeloid Leukemia beyond 2016: Important Questions
Professor Hagop Kantarjian

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston (USA)

  • CML - few key studies
  • CML survival rates
  • CML - important questions
  • CML frontline RX
  • Optimal dose for second TKI's
  • CML therapy in 2016
  • CML - potential molecular cures
  • Cost-benefit of TKI's
  • Criteria for response/failure and change of RX
  • CML - role and timing of allo SCT
  • Therapy of CML transformation
  • Detection of mutations in CML
Please note: 
There is currently no web stream available of this presentation and you can only see the slides. 

 

 
Branford keynote JGM 2016   

Keynote iCMLf Prize 2016:

Challenges for monitoring patients in emerging economic regions
Associate Professor Susan Branford

Centre for Cancer Biology, SA Pathology and Universities of Adelaide and South Australia (Australia)

  • Quantitative PCR - from the 1st patient tested to treatment-free remission
  • First time monitoring for 30 patients from the Philippines in 2011
  • Point of care monitoring
  • The evolution of BCR-ABL1 molecular testing from 2000-2016
  • iCMLf supporting clinician and scientist training in expert centres
  • Testing in the Philippines in 2016
  • 30 patients tested for mutations in Adelaide 2015
  • Molecular monitoring - unmet needs
  • CML monitoring circa 2016 - a future outlook